Zasocitinib (TAK-279), a Selective, Oral TYK2 Inhibitor, Reduces Body Surface Area Involvement in a Phase 2b Trial in Moderate-to-Severe Plaque Psoriasis. J of Skin 2024, 8 (6), s441. https://doi.org/10.25251/skin.8.supp.441.